Essential thrombocythemia: Biology, clinical features, thrombotic risk, therapeutic options and outcome
Open Access
- 2 September 2019
- journal article
- Published by Heighten Science Publications Corporation in Journal of Hematology and Clinical Research
- Vol. 3 (1), 053-059
- https://doi.org/10.29328/journal.jhcr.1001012
Abstract
No abstract availableThis publication has 67 references indexed in Scilit:
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)Blood, 2012
- Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteriaLeukemia, 2011
- The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia veraEuropean Journal of Haematology, 2010
- A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasmsBritish Journal of Haematology, 2010
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1Leukemia, 2010
- Prevalence of polycythemia vera and essential thrombocythemiaAmerican Journal of Hematology, 2008
- MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid MetaplasiaPLoS Medicine, 2006
- Epidemiology of the Myeloproliferative Disorders Polycythemia Vera and Essential ThrombocythemiaSeminars in Thrombosis and Hemostasis, 2006
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersThe New England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005